Prognostic importance of sodium level trajectory in acute heart failure

[1]  A. Voors,et al.  Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction , 2017, Clinical Research in Cardiology.

[2]  M. Yoshiyama,et al.  Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction , 2017, Heart and Vessels.

[3]  K. Sugi,et al.  Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction. , 2016, International journal of cardiology.

[4]  D. Bates,et al.  Impact of Hyponatremia Correction on the Risk for 30-Day Readmission and Death in Patients with Congestive Heart Failure. , 2016, The American journal of medicine.

[5]  R. Starling,et al.  Transient Hyponatremia During Hospitalization for Acute Heart Failure. , 2016, The American journal of medicine.

[6]  K. Sugi,et al.  Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction. , 2016, Journal of cardiac failure.

[7]  T. Kume,et al.  Recovery from hyponatremia in acute phase is associated with better in-hospital mortality rate in acute heart failure syndrome. , 2016, Journal of cardiology.

[8]  Wen-Chung Yu,et al.  Hyponatremia and Worsening Sodium Levels Are Associated With Long‐Term Outcome in Patients Hospitalized for Acute Heart Failure , 2016, Journal of the American Heart Association.

[9]  R. Matsukawa,et al.  Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure , 2016, Heart and Vessels.

[10]  G. Navis,et al.  Diuretic response in acute heart failure—pathophysiology, evaluation, and therapy , 2015, Nature Reviews Cardiology.

[11]  W. Tang,et al.  Hyponatremia in acute decompensated heart failure: depletion versus dilution. , 2015, Journal of the American College of Cardiology.

[12]  N. Sato.  Awareness of the vasopressin system in heart failure. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[13]  A. Takahashi,et al.  Clinical Effectiveness of Tolvaptan in Patients with Acute Decompensated Heart Failure and Renal Failure: Design and Rationale of the AQUAMARINE Study , 2014, Cardiovascular Drugs and Therapy.

[14]  K. Swedberg,et al.  Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. , 2013, Journal of cardiac failure.

[15]  L. Price,et al.  Outcome Differences in Community- Versus Hospital-Acquired Hyponatremia in Patients With a Diagnosis of Heart Failure , 2013, Circulation. Heart failure.

[16]  M. Cho,et al.  Improvement of hyponatraemia during hospitalisation for acute heart failure is not associated with improvement of prognosis: an analysis from the Korean Heart Failure (KorHF) registry , 2012, Heart.

[17]  R. Doughty,et al.  Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta‐analysis † , 2012, European journal of heart failure.

[18]  M. Isobe,et al.  Progression of hyponatremia is associated with increased cardiac mortality in patients hospitalized for acute decompensated heart failure. , 2012, Journal of cardiac failure.

[19]  M. Rich,et al.  Impact of Change in Serum Sodium Concentration on Mortality in Patients Hospitalized With Heart Failure and Hyponatremia , 2011, Circulation. Heart failure.

[20]  陶仲为,et al.  Hyponatremia , 2010 .

[21]  G. Fonarow,et al.  Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. , 2007, European heart journal.

[22]  R. Califf,et al.  Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study , 2005, Circulation.

[23]  R. Oren.  Hyponatremia in congestive heart failure. , 2005, The American journal of cardiology.

[24]  Christopher M O'Connor,et al.  Risk stratification after hospitalization for decompensated heart failure. , 2004, Journal of cardiac failure.

[25]  Peter C Austin,et al.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.

[26]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[27]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[28]  T. Berl,et al.  Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. , 1981, The New England journal of medicine.